Saturday, February 10, 2018 02:00 AM

TWO DRUGS OFFER HOPE AGAINST A TOUGH-TO-TREAT PROSTATE CANCER

By Dennis ThompsonHealthDay Reporter

THURSDAY, Feb. 8, 2018 (HealthDay News) -- Two cancer[1] drugs[2] can stall the progression of a particularly hard-to-treat form of prostate cancer[3], a pair of new trials shows.

Both a newly developed drug called apalutamide and an already approved drug called enzalutamide (Xtandi) kept prostate cancer[4] from spreading for two years in men whose disease had not yet traveled to other parts of their bodies.

Men newly diagnosed with prostate cancer that hasn't spread are first treated with androgen[5]-deprivation therapy -- a medication that robs the tumor[6] of the testosterone that helps fuel its growth, said Dr. Matthew Smith, lead researcher of the apalutamide trial. He is director of the genitourinary malignancies program at Massachusetts General Hospital, in Boston.

"It always works, and it almost always stops working," ...

News source: MedicineNet

See also: The Robotic Urologist